Amy Cyr is an Oncology physician affiliated with Washington University in St. Louis. OpenAlex indexes 92 publications with 4,266 citations (h-index 22); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5225 Mid America Plz
Div Im Medical Oncology, Ste D115
Saint Louis, MO 631290002
Telephone
800-647-2098Registry record last updated 17 Apr 2025.
Clinical trials
- Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Stryker CorporationProgram year20251 payment
- Dilon Technologies, Inc.Program year20241 payment
- Stryker CorporationProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
75.6%Aromatase Inhibitor55.4%Anastrozole55%Exemestane38%Letrozole7%Part D<11 patientsEstrogen Agonist/Antagonist20.2%Tamoxifen Citrate100%Part D≥23 patientsGenitourinary & hormones
21.4%Estrogen Agonist/Antagonist21.4%Raloxifene Hcl100%Part D≥25 patientsNervous system
3%SSRI3%Escitalopram Oxalate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Individualizing Breast Cancer Risk Assessment in Clinical Practice
Surgical Oncology Clinics of North America
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Randall Bateman, MD
Washington University in St. Louis
Janet McGill, MD
Washington University in St. Louis
Robert Carney, MD
Washington University in St. Louis
David Clifford, MD
Washington University in St. Louis
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”